Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR | Market Cap | 139.82B -1.6% |
| Revenue (ttm) | 20.92B +10.7% |
| Net Income | 6.14B +19.1% |
| EPS | 80.50 +19.4% |
| Shares Out | 76.01M |
| PE Ratio | 22.85 |
| Forward PE | 20.67 |
| Dividend | 6.00 (0.34%) |
| Ex-Dividend Date | n/a |
| Volume | 6,431 |
| Average Volume | 6,595 |
| Open | 1,735.05 |
| Previous Close | 1,735.90 |
| Day's Range | 1,728.05 - 1,774.25 |
| 52-Week Range | 1,502.45 - 2,396.95 |
| Beta | 0.16 |
| RSI | 66.72 |
| Earnings Date | May 15, 2026 |
About Caplin Point Laboratories
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, p... [Read more]
Financial Performance
In fiscal year 2025, Caplin Point Laboratories's revenue was 19.40 billion, an increase of 14.35% compared to the previous year's 16.96 billion. Earnings were 5.36 billion, an increase of 17.33%.
Financial StatementsNews
Caplin Point subsidiary receives USFDA approval for Calcium Gluconate Injection; targets $71 million US market
Caplin Steriles Limited (CSL), the wholly owned subsidiary of Caplin Point Laboratories Limited, has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbrevia...
Caplin Point receives USFDA approval for potassium phosphates injection
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories, has secured final approval from the USFDA for its potassium phosphates injection. The product is a generic equivalent of Fresenius K...
Caplin Point Laboratories arm receives USFDA approval for potassium phosphates injection
Caplin Point Laboratories announced that its subsidiary Caplin Steriles Limited has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug App...
Caplin Point subsidiary secures USFDA final approval for Desmopressin Acetate Injection ANDA
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final approval from...
Caplin Point subsidiary secures USFDA approval for Sodium Phosphates Injection
Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited (BSE: 524742 | NSE: CAPLIPOINT), has secured final...
Caplin Point Laboratories Ltd (BOM:524742) Q3 2026 Earnings Call Highlights: Navigating Growth ...
Caplin Point Laboratories Ltd (BOM:524742) Q3 2026 Earnings Call Highlights: Navigating Growth and Compliance Amidst Challenges
Q3 2026 Caplin Point Laboratories Ltd Earnings Call Transcript
Q3 2026 Caplin Point Laboratories Ltd Earnings Call Transcript
Caplin Point Laboratories Transcript: Q3 25/26
Q3 FY26 saw double-digit revenue and profit growth, margin expansion, and strong cash flow. US and Latin America drive future growth, with new product launches, regulatory approvals, and major CapEx investments supporting long-term expansion.
Caplin Point subsidiary receives USFDA approval for Methylprednisolone Acetate Injectable
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the United States Food and...
Caplin Point Laboratories subsidiary secures USFDA approval for Generic Linezolid Injection
Caplin Steriles Limited, the subsidiary of Caplin Point Laboratories, has received final approval from the US Food and Drug Administration...
Caplin Point Laboratories subsidiary receives USFDA approval for Acetaminophen Injection ANDA
Caplin Steriles Limited, the sterile injectables subsidiary of Caplin Point Laboratories Limited, has secured final approval from the United States...
Caplin Point Laboratories Ltd (BOM:524742) Q2 2026 Earnings Call Highlights: Strong Revenue ...
Caplin Point Laboratories Ltd (BOM:524742) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion Plans
Q2 2026 Caplin Point Laboratories Ltd Earnings Call Transcript
Q2 2026 Caplin Point Laboratories Ltd Earnings Call Transcript
Caplin Point Laboratories Transcript: Q2 25/26
Revenue and profit margins grew strongly in H1 FY26, with PAT up 21.6% and EBITDA margin expanding. Expansion in the U.S., Mexico, and Latin America, along with robust cash reserves, positions the company for continued growth and potential acquisitions.
Caplin Point subsidiary gets USFDA nod for Milrinone Lactate in 5% Dextrose Injection
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742, NSE: CAPLIPOINT), has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...
Caplin Point Laboratories Transcript: Q1 25/26
Q1 FY2026 delivered 11.7% revenue growth and 20.7% PAT growth, driven by strong Latin America and U.S. performance, robust margins, and a focus on asset-light models. Management projects continued double-digit growth, with new product launches and CapEx supporting future expansion.
Caplin Point shares surge 5% as Q1 revenue jumps 11% YoY to Rs 510 crore, net profit up 23.2% YoY
Caplin Point Laboratories witnessed a strong rally in its stock price on Thursday, surging over 5% after the company posted robust Q1 FY26 results. The stock opened at ₹1,900 and climbed as high as ₹2...
Caplin Point subsidiary to acquire Mexican pharma firm Triwin Pharma S.A. DE C.V.
Caplin Point Laboratories, through its wholly owned subsidiary Caplin Point Far East Limited based in Hong Kong, has entered into a Share Purchase Agreement dated June 3, 2025, to acquire the entire s...
Caplin Point Laboratories Transcript: Q4 24/25
Revenue grew 15% to INR 2,034 crore and PAT rose 17% to INR 541 crore, with record margins and strong liquidity. U.S. and Latin America expansions, new product launches, and disciplined capital allocation underpin a focus on sustainable, high-quality growth.
Caplin Point Q4 results: Revenue up 10.9% YoY to Rs 502.45 crore, Net profit rises 19.8% YoY
Caplin Point Laboratories Ltd reported a consolidated net profit of ₹145.28 crore for the quarter ended March 31, 2025, marking a 19.8% increase compared to ₹121.23 crore in the same quarter last year...
Caplin Point Laboratories subsidiary receives USFDA approval for Haloperidol Decanoate Injection
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited (BSE: 524742, NSE: CAPLIPOINT), has received final approval from the United States Food and Drug Administration (USFDA) for i...
Caplin Point subsidiary Caplin Steriles gets USFDA approval for Phytonadione Injectable Emulsion
Caplin Steriles Limited, a wholly owned subsidiary of Caplin Point Laboratories Limited, has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New ...
Caplin Point Laboratories shares jump over 3% after acquiring Neoethicals Chile SpA
Shares of Caplin Point Laboratories surged 3.06% to Rs 2,038.00 during Wednesday’s session after the company announced a strategic acquisition through its Hong Kong-based subsidiary. Caplin Point Far ...
Caplin Point subsidiary secures USFDA approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution
Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Limited, has received final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Applica...
Caplin Point Laboratories Transcript: Q3 24/25
Nine-month FY25 revenue and profits surpassed FY23 full-year levels, driven by strong U.S. and LATAM growth, robust margins, and a strategic shift to own-label launches in the U.S. Expansion into Mexico and Chile, new product approvals, and internal funding support a positive multi-year outlook.